Replies to post #30568 on Biotech Values

[ThomasS]

IDIX: Dew, as usual, you distort the facts to suit your motives:

Note I said "other competitors" in the HCV space, not specifically ANDS.
Now, how are you going to justify your investment in IDIX at >$10? ANDS isn't the reason for the IDIX decline...look elsewhere...

"ANDS: Between ANA 380 for HBV and ANA 975 for HCV, I don't know how IDIX can effectively compete, especially in the HCV space against other competitors. Their HBV drug already faces challengers..."

"We are very pleased with ANA380's promising clinical results and believe they emphasize ANA380's potential as the next generation therapy for HBV patients," said In-Chull Kim, Ph.D., President and Chief Executive Officer of LG Life Sciences."